NEWS HIGHLIGHTSMedia Articles Related to Inversine (Mecamylamine)
FDA Approves Intravenous Formulation Of Pfizer's Revatio(R) (Sildenafil) For The Treatment Of Pulmonary Arterial Hypertension
Source: Health News from Medical News Today [2009.11.23]
Pfizer announced that the U.S. Food and Drug Administration (FDA) has approved Revatio® (sildenafil) Injection, an intravenous formulation of Revatio. Revatio is the only FDA-approved phosphodiesterase-5 (PDE5) inhibitor available in both tablet and intravenous formulations.
New Consortium Paves The Way For Improved Treatment Of Hypertension And Associated Vascular Complications
Source: Hypertension News From Medical News Today [2009.11.18]
Top Institute Pharma (TI Pharma) has formed a consortium with Actelion Pharmaceuticals Ltd, Erasmus Medical Centre and Maastricht University to define new modalities for the treatment of hypertension (high blood pressure) and associated vascular complications such as heart and kidney failure, myocardial infarction and stroke.
Kids with CKD Often Have Masked Hypertension (CME/CE)
Source: MedPage Today Nephrology [2009.11.13]
Many children with chronic kidney disease may have undetected hypertension, placing them at risk for enlarged hearts and future cardiovascular disease, a cross-sectional study showed.
Key Player Identified In Cascade That Leads To Hypertension-Related Kidney Damage
Source: Hypertension News From Medical News Today [2009.11.06]
A key player in a cascade that likely begins with stress and leads to high blood pressure and kidney damage has been identified by researchers who say the finding may lead to better ways to control both. Medical College of Georgia researchers have found endothelin, a powerful blood vessel constrictor and inflammatory peptide, increases the number of T cells in the kidneys, which helps recruit other immune cells, causing inflammation and destruction.
A Recipe For Hypertension: High Fructose Corn Syrup
Source: Hypertension News From Medical News Today [2009.10.31]
A diet high in fructose increases the risk of developing high blood pressure (hypertension), according to a paper presented at the American Society of Nephrology's 42nd Annual Meeting and Scientific Exposition in San Diego, California. The findings suggest that cutting back on processed foods and beverages that contain high fructose corn syrup (HFCS) may help prevent hypertension.
Published Studies Related to Inversine (Mecamylamine)
Effects of acute ultra-low dose mecamylamine on cognition in adult attention-deficit/hyperactivity disorder (ADHD). [2009.06]
OBJECTIVE: Nicotinic cholinergic stimulation has known beneficial effects in attention-deficit/hyperactivity disorder (ADHD). Mecamylamine is a non-competitive nicotinic antagonist which is reported in several animal studies to have paradoxical positive effects on cognition at ultra-low doses. Comparable studies in humans have not been conducted. The aim of this study was to determine the effects of acute ultra-low doses of mecamylamine on cognition in adult ADHD... CONCLUSION: This is the first study to find measurable effects of ultra-low doses of mecamylamine in humans. Mecamylamine did not improve core ADHD cognitive symptoms, but significantly improved recognition memory. These effects may represent mixed receptor activity (activation and blockade) at the doses tested. The finding of beneficial effects on memory processes has important clinical implications and further exploration of this effect is warranted.
A randomized, controlled trial to assess the efficacy and safety of a transdermal delivery system of nicotine/mecamylamine in cigarette smokers. [2007.05]
AIMS: To determine the efficacy and safety of nicotine transdermal therapy co-administered with the nicotine antagonist, mecamylamine, compared to a nicotine transdermal patch alone (21 mg nicotine + 6 mg mecamylamine, 21 mg nicotine + 3 mg mecamylamine, and 21 mg nicotine + 0 mg mecamylamine)... CONCLUSION: If adding mecamylamine to nicotine replacement therapy (NRT) improves the chances of success at stopping smoking, the results of this study suggest that the effect is very small.
A randomized, controlled trial to assess the efficacy and safety of a transdermal delivery system of nicotine/mecamylamine in cigarette smokers. [2007.03.01]
Aims To determine the efficacy and safety of nicotine transdermal therapy co-administered with the nicotine antagonist, mecamylamine, compared to a nicotine transdermal patch alone (21 mg nicotine + 6 mg mecamylamine, 21 mg nicotine + 3 mg mecamylamine, and 21 mg nicotine + 0 mg mecamylamine)...
The influence of mecamylamine on trigeminal and olfactory chemoreception of nicotine. [2006.02]
Nicotine presented to the nasal cavity at low concentrations evokes 'odorous' sensations, and at higher concentrations 'burning' and 'stinging' sensations. A study in smokers and nonsmokers provided evidence of a relationship between the experience with the pharmacological action of S-(-)-nicotine and the perceived pleasantness/unpleasantness following nasal stimulation with S-(-)-nicotine...
Mecamylamine and ethanol preference in healthy volunteers. [2005.01]
BACKGROUND: Recent evidence suggests that some of the behavioral effects of alcohol may be mediated through actions on nicotinic acetylcholine receptors. Mecamylamine, a nicotinic acetylcholine receptor antagonist, reduces alcohol preference and consumption in alcohol-preferring rats, and in humans, mecamylamine dampens some of the subjective, or mood-altering, effects of alcohol. This experiment was designed to investigate the effects of mecamylamine on consumption of alcohol in healthy social drinkers... CONCLUSION: These results provide only limited support for the idea that nicotinic acetylcholine receptors are involved in the rewarding effects of alcohol.
Clinical Trials Related to Inversine (Mecamylamine)
Study of the Effects of Mecamylamine and Varenicline in Schizophrenia [Recruiting]
We are conducting this study to find out if blocking or partially stimulating the effects of
nicotine in the brain can affect memory and concentration. Nicotine is the addictive drug
found in tobacco products. Our subjects will be people with and without mental illness
(schizophrenia), smokers and non-smokers.
We will use a medication called mecamylamine (Inversine) to block the effects of nicotine on
the brains of our subjects. We will also use a medication called varenicline (Chantix) to
partially increase the effects of nicotine on the brains of our subjects. This study also
uses a placebo, a pill that does not have any active ingredients but looks exactly like the
mecamylamine and varenicline pills. We will compare the effects of giving mecamylamine or
placebo to people who have schizophrenia and people who do not have schizophrenia.
We know that people with schizophrenia smoke heavily and find it harder to stop smoking than
most other people do. Studies have shown that people with schizophrenia may smoke more
because nicotine helps their concentration and memory. We are interested in helping people
with schizophrenia smoke less. Mecamylamine blocks the parts of the brain that react to
nicotine and varenicline partially stimulates and partially blocks the parts of the brain
that react to nicotine. Both medications may decrease the effects that smoking has on the
body.
Flexible Dose Titration Add-on Study to Treat Major Depressive Disorder [Completed]
Depressed patients will receive 6 weeks of citaloprma (20-40mg) therapy. Subjects who have
an inadequate response (partial or non-responder) will be randomized to receive either
mecamylamine (5-10mg) or placebo added to their citalopram for a further 8 weeks.
Nicotinic Receptor Augmentation of SSRI Antidepressants [Completed]
The purpose of this study is to determine whether the nicotinic receptor antagonist
mecamylamine hydrochloride (Inversine) can augment SSRI-refractory major depression symptoms,
quality of life and cigarette smoking outcomes. A total of n=60 SSRI-refractory patients who
are on stable doses of an SSRI are being recruited into this 8-week double-blind, randomized,
placebo-controlled trial.
A Pilot Trial of Mecamylamine for the Treatment of Autism [Recruiting]
Treatment With Mecamylamine in Smoking and Non-Smoking Alcohol Dependent Patients [Recruiting]
The purpose of the study will be to evaluate the efficacy of mecamylamine in reducing
alcohol consumption in smoking and non-smoking alcohol dependent patients.
We hypothesize that mecamylamine will result in a greater reduction of alcohol consumption
than placebo. We further hypothesize that mecamylamine will be effective in reducing both
alcohol consumption and smoking in a subset of alcoholics who also smoke.
|
